This summary provides the results of a study of two treatments for cancer, enfortumab vedotin and pembrolizumab, that were studied together against locally advanced or metastatic urothelial cancer (la/mUC), a cancer that occurs most commonly in the bladder.This Plain Language Summary of Publication article from Future Oncology summarises a study looking at two treatments enfortumab vedotin and pembrolizumab that were studied to treat individuals with locally advanced or metastatic urothelial cancer, which often occurs in the bladder.

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer’ and was published in Journal of Clinical Oncology

Visit ASCO Publications using the link to read the original article.